{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:15:47Z","timestamp":1783062947776,"version":"3.54.6"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"crossref","award":["IN606A-2024\/016"],"award-info":[{"award-number":["IN606A-2024\/016"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"crossref","award":["PID2022-138936OB-C31"],"award-info":[{"award-number":["PID2022-138936OB-C31"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"DOI":"10.1007\/s10571-026-01752-4","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:45:24Z","timestamp":1782283524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Biomarkers for Alzheimer\u2019s Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies"],"prefix":"10.1007","volume":"46","author":[{"given":"Mar\u00eda","family":"de los \u00c1ngeles Fern\u00e1ndez-Ceballos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Carlos","family":"Ag\u00eds-Balboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1752_CR170","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.nbd.2013.09.011","volume":"62","author":"HY Agbemenyah","year":"2014","unstructured":"Agbemenyah HY, Agis-Balboa RC, Burkhardt S, Delalle I, Fischer A (2014) Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiol Dis 62:135\u2013143. https:\/\/doi.org\/10.1016\/j.nbd.2013.09.011","journal-title":"Neurobiol Dis"},{"issue":"19","key":"1752_CR6","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.15252\/embj.201796821","volume":"36","author":"RC Ag\u00eds-Balboa","year":"2017","unstructured":"Ag\u00eds-Balboa RC, Pinheiro PS, Rebola N, Kerimoglu C, Benito E, Gertig M et al (2017) Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. EMBO J 36(19):2815\u20132828. https:\/\/doi.org\/10.15252\/embj.201796821","journal-title":"EMBO J"},{"key":"1752_CR152","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarim\u00f3n J, Carmona-Iragui M, Ill\u00e1n-Gala I, Morenas-Rodr\u00edguez E, Barroeta I et al (2019) The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y) 5:597\u2013609. https:\/\/doi.org\/10.1016\/j.trci.2019.09.005","journal-title":"Alzheimers Dement (N Y)"},{"key":"1752_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12492","author":"M Ally","year":"2023","unstructured":"Ally M, Sugarman MA, Zetterberg H, Blennow K, Ashton NJ, Karikari TK et al (2023) Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. https:\/\/doi.org\/10.1002\/dad2.12492","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"1752_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2018.03.006","author":"M Altuna-Azkargorta","year":"2018","unstructured":"Altuna-Azkargorta M, Mendioroz-Iriarte M (2018) Blood biomarkers in Alzheimer\u2019s disease. Neurologia. https:\/\/doi.org\/10.1016\/j.nrl.2018.03.006","journal-title":"Neurologia"},{"issue":"3","key":"1752_CR120","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3233\/JAD-215093","volume":"86","author":"L \u00c1lvarez-S\u00e1nchez","year":"2022","unstructured":"\u00c1lvarez-S\u00e1nchez L, Pe\u00f1a-Bautista C, Baquero M, Ch\u00e1fer-Peric\u00e1s C (2022) Novel ultrasensitive detection technologies for the identification of early and minimally invasive Alzheimer\u2019s disease blood biomarkers. J Alzheimers Dis 86(3):1337\u20131369. https:\/\/doi.org\/10.3233\/JAD-215093","journal-title":"J Alzheimers Dis"},{"key":"1752_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.dadm.2016.05.005","volume":"3","author":"U Andreasson","year":"2016","unstructured":"Andreasson U, Blennow K, Zetterberg H (2016) Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement Amst Neth 3:98\u2013102. https:\/\/doi.org\/10.1016\/j.dadm.2016.05.005","journal-title":"Alzheimers Dement Amst Neth"},{"issue":"11","key":"1752_CR84","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acn3.51670","volume":"9","author":"AJ Aschenbrenner","year":"2022","unstructured":"Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P et al (2022) Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol 9(11):1739\u20131751. https:\/\/doi.org\/10.1002\/acn3.51670","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1752_CR114","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortob\u00e1gyi T, H\u00f6glund K et al (2019) Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 7(1):5\u20135. https:\/\/doi.org\/10.1186\/s40478-018-0649-3","journal-title":"Acta Neuropathol Commun"},{"key":"1752_CR67","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.11.23292493","author":"NJ Di Ashton","year":"2023","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonatis E et al (2023) Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv. https:\/\/doi.org\/10.1101\/2023.07.11.23292493","journal-title":"medRxiv"},{"issue":"5","key":"1752_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol (Berl) 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6","key":"1752_CR91","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1017\/S1355617721000813","volume":"28","author":"BM Asken","year":"2022","unstructured":"Asken BM, VandeVrede L, Rojas JC, Fonseca C, Staffaroni AM, Elahi FM et al (2022) Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment. J Int Neuropsychol Soc 28(6):588\u2013599. https:\/\/doi.org\/10.1017\/S1355617721000813","journal-title":"J Int Neuropsychol Soc"},{"issue":"4","key":"1752_CR172","doi-asserted-by":"publisher","first-page":"928","DOI":"10.14283\/jpad.2024.67","volume":"11","author":"S Aye","year":"2024","unstructured":"Aye S, Handels R, Winblad B, J\u00f6nsson L (2024) Optimising Alzheimer\u2019s disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment. J Prev Alzheimers Dis 11(4):928\u2013942. https:\/\/doi.org\/10.14283\/jpad.2024.67","journal-title":"J Prev Alzheimers Dis"},{"key":"1752_CR30","doi-asserted-by":"publisher","first-page":"624330","DOI":"10.3389\/fnagi.2021.624330","volume":"13","author":"W Bao","year":"2021","unstructured":"Bao W, Xie F, Zuo C, Guan Y, Huang YH (2021) PET neuroimaging of Alzheimer\u2019s disease: radiotracers and their utility in clinical research. Front Aging Neurosci 13:624330\u2013624330. https:\/\/doi.org\/10.3389\/fnagi.2021.624330","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1752_CR103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/JAD-200901","volume":"79","author":"W Barker","year":"2021","unstructured":"Barker W, Quinonez C, Greig MT, Behar R, Chirinos C, Rodriguez RA et al (2021) Utility of plasma neurofilament light in the 1Florida Alzheimer\u2019s Disease Research Center (ADRC). J Alzheimers Dis 79(1):59\u201370. https:\/\/doi.org\/10.3233\/JAD-200901","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1752_CR101","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM et al (2021) Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther 13(1):198\u2013198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1752_CR50","doi-asserted-by":"publisher","first-page":"e70209","DOI":"10.1002\/alz.70209","volume":"21","author":"B Bellaver","year":"2025","unstructured":"Bellaver B, Povala G, Ferreira PCL, Bauer-Negrini G, Lussier FZ, Leffa DT et al (2025) Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 21(5):e70209\u2013e70209. https:\/\/doi.org\/10.1002\/alz.70209","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"12","key":"1752_CR111","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1093\/brain\/awaa342","volume":"143","author":"AL Benedet","year":"2020","unstructured":"Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M et al (2020) Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease. Brain 143(12):3793\u20133804. https:\/\/doi.org\/10.1093\/brain\/awaa342","journal-title":"Brain"},{"issue":"12","key":"1752_CR96","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471\u20131471. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","journal-title":"JAMA Neurol"},{"issue":"3","key":"1752_CR75","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/alz.12745","volume":"19","author":"L Beyer","year":"2023","unstructured":"Beyer L, Stocker H, Rujescu D, Holleczek B, Stockmann J, Nabers A et al (2023) Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years. Alzheimers Dement 19(3):1020\u20131028. https:\/\/doi.org\/10.1002\/alz.12745","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1752_CR130","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M et al (2022) The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res Ther 14(1):195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1752_CR64","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41398-023-02558-4","volume":"13","author":"M Bucci","year":"2023","unstructured":"Bucci M, Bluma M, Savitcheva I, Ashton NJ, Chiotis K, Matton A et al (2023) Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Transl Psychiatry 13(1):268\u2013268. https:\/\/doi.org\/10.1038\/s41398-023-02558-4","journal-title":"Transl Psychiatry"},{"key":"1752_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae451","author":"R Cacciaglia","year":"2024","unstructured":"Cacciaglia R, Shekari M, Salvad\u00f3 G, Mil\u00e0-Alom\u00e0 M, Falcon C, S\u00e1nchez-Benavides G et al (2024) The CSF p-tau\/\u03b2-amyloid 42 ratio correlates with brain structure and fibrillary \u03b2-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer\u2019s disease. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcae451","journal-title":"Brain Commun"},{"issue":"2","key":"1752_CR169","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/biomedicines11020273","volume":"11","author":"S Campanioni","year":"2023","unstructured":"Campanioni S, Gonz\u00e1lez-N\u00f3voa JA, Busto L, Ag\u00eds-Balboa RC, Veiga C (2023) Data-driven phenotyping of Alzheimer\u2019s disease under epigenetic conditions using partial volume correction of PET studies and manifold learning. Biomedicines 11(2):273\u2013273. https:\/\/doi.org\/10.3390\/biomedicines11020273","journal-title":"Biomedicines"},{"issue":"7","key":"1752_CR168","doi-asserted-by":"publisher","first-page":"e0306999","DOI":"10.1371\/journal.pone.0306999","volume":"19","author":"S Campanioni","year":"2024","unstructured":"Campanioni S, Veiga C, Prieto-Gonz\u00e1lez JM, Gonz\u00e1lez-N\u00f3voa JA, Busto L, Martinez C et al (2024) Explainable machine learning on baseline MRI predicts multiple sclerosis trajectory descriptors. PLoS ONE 19(7):e0306999\u2013e0306999. https:\/\/doi.org\/10.1371\/journal.pone.0306999","journal-title":"PLoS ONE"},{"key":"1752_CR125","unstructured":"Celerion Switzerland AG Celerion (2026) Developing an ultrasensitive PK assay using SIMOA: step-by-step to the target. https:\/\/www.celerion.com\/resource\/developing-an-ultrasensitive-pk-assay-using-simoa-step-by-step-to-the-target. Cited 4 Mar 2026"},{"issue":"1","key":"1752_CR167","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13195-025-01851-2","volume":"17","author":"HI Chang","year":"2025","unstructured":"Chang HI, Ma MC, Huang KL, Huang CG, Huang SH, Huang CW et al (2025) Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):194\u2013194. https:\/\/doi.org\/10.1186\/s13195-025-01851-2","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1752_CR112","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JAD-190533","volume":"71","author":"P Chatterjee","year":"2019","unstructured":"Chatterjee P, Elmi M, Goozee K, Shah T, Sohrabi HR, Dias CB et al (2019) Ultrasensitive detection of plasma amyloid-\u03b2 as a biomarker for cognitively normal elderly individuals at risk of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 71(3):775\u2013783. https:\/\/doi.org\/10.3233\/JAD-190533","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"1752_CR98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR et al (2021) Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry 11(1):27\u201327. https:\/\/doi.org\/10.1038\/s41398-020-01137-1","journal-title":"Transl Psychiatry"},{"issue":"5","key":"1752_CR155","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","volume":"12","author":"C Chen","year":"2025","unstructured":"Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K et al (2025) Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(5):100160\u2013100160. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100160","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1752_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N et al (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13(1):68\u201368. https:\/\/doi.org\/10.1186\/s13195-021-00804-9","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1752_CR56","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/ijms25021173","volume":"25","author":"L Colmant","year":"2024","unstructured":"Colmant L, Boyer E, Gerard T, Sleegers K, Lhommel R, Ivanoiu A et al (2024) Definition of a threshold for the plasma A\u03b242\/A\u03b240 ratio measured by single-molecule array to predict the amyloid status of individuals without dementia. Int J Mol Sci 25(2):1173\u20131173. https:\/\/doi.org\/10.3390\/ijms25021173","journal-title":"Int J Mol Sci"},{"key":"1752_CR63","doi-asserted-by":"publisher","first-page":"110680","DOI":"10.1016\/j.clinbiochem.2023.110680","volume":"121\u2013122","author":"JG Cooper","year":"2023","unstructured":"Cooper JG, Stukas S, Ghodsi M, Ahmed N, Diaz-Arrastia R, Holmes DT et al (2023) Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population. Clin Biochem 121\u2013122:110680\u2013110680. https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110680","journal-title":"Clin Biochem"},{"key":"1752_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM et al (2025) Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement Transl Res Clin Interv. https:\/\/doi.org\/10.1002\/trc2.70098","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"1752_CR140","doi-asserted-by":"publisher","first-page":"1463001","DOI":"10.3389\/fbinf.2024.1463001","volume":"4","author":"YR Dan","year":"2024","unstructured":"Dan YR, Chiam KH (2024) Discovery of plasma biomarkers related to blood-brain barrier dysregulation in Alzheimer\u2019s disease. Front Bioinforma 4:1463001\u20131463001. https:\/\/doi.org\/10.3389\/fbinf.2024.1463001","journal-title":"Front Bioinforma"},{"issue":"3","key":"1752_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/arclin\/acae019","volume":"39","author":"HE Dark","year":"2024","unstructured":"Dark HE, Duggan MR, Walker KA (2024) Plasma biomarkers for Alzheimer\u2019s and related dementias: a review and outlook for clinical neuropsychology. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol 39(3):313\u2013324. https:\/\/doi.org\/10.1093\/arclin\/acae019","journal-title":"Arch Clin Neuropsychol Off J Natl Acad Neuropsychol"},{"issue":"1","key":"1752_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-024-01459-y","volume":"16","author":"HE Dark","year":"2024","unstructured":"Dark HE, An Y, Duggan MR, Joynes C, Davatzikos C, Erus G et al (2024) Alzheimer\u2019s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimers Res Ther 16(1):94\u201394. https:\/\/doi.org\/10.1186\/s13195-024-01459-y","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1752_CR88","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acn3.51553","volume":"9","author":"S De Meyer","year":"2022","unstructured":"De Meyer S, Vanbrabant J, Schaeverbeke JM, Reinartz M, Luckett ES, Dupont P et al (2022) Phospho-specific plasma p\u2010tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease. Ann Clin Transl Neurol 9(5):734\u2013746. https:\/\/doi.org\/10.1002\/acn3.51553","journal-title":"Ann Clin Transl Neurol"},{"key":"1752_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1667402","author":"B Deng","year":"2025","unstructured":"Deng B, Zheng Y, Gao Y, Zhuang Y, Ma L, Cao L (2025) Evaluation of the diagnostic efficacy of core biomarkers in cerebrospinal fluid for Alzheimer\u2019s disease: a systematic review and meta-analysis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2025.1667402","journal-title":"Front Neurol"},{"issue":"2","key":"1752_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3233\/JAD-230932","volume":"96","author":"Y Dong","year":"2023","unstructured":"Dong Y, Hou T, Li Y, Liu R, Cong L, Liu K et al (2023) Plasma amyloid-\u03b2, total tau, and neurofilament light chain across the Alzheimer\u2019s disease clinical spectrum: a population-based study. J Alzheimers Dis JAD 96(2):845\u2013858. https:\/\/doi.org\/10.3233\/JAD-230932","journal-title":"J Alzheimers Dis JAD"},{"key":"1752_CR36","doi-asserted-by":"publisher","first-page":"125529","DOI":"10.1016\/j.talanta.2023.125529","volume":"270","author":"R Dong","year":"2024","unstructured":"Dong R, Yi N, Jiang D (2024) Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules. Talanta 270:125529\u2013125529. https:\/\/doi.org\/10.1016\/j.talanta.2023.125529","journal-title":"Talanta"},{"issue":"6","key":"1752_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2174\/156720512801322582","volume":"9","author":"G D\u2019Onofrio","year":"2012","unstructured":"D\u2019Onofrio G, Sancarlo D, Panza F, Copetti M, Cascavilla L, Paris F et al (2012) Neuropsychiatric symptoms and functional status in Alzheimer\u2019s disease and vascular dementia patients. Curr Alzheimer Res 9(6):759\u2013771. https:\/\/doi.org\/10.2174\/156720512801322582","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"1752_CR129","first-page":"A07220446","volume":"70","author":"SU Ebbesen","year":"2023","unstructured":"Ebbesen SU, H\u00f8gh P, Zibrandtsen I (2023) Plasma A\u03b2 biomarker for early diagnosis and prognosis of Alzheimer\u2019s disease - a systematic review. Dan Med J 70(6):A07220446","journal-title":"Dan Med J"},{"key":"1752_CR137","doi-asserted-by":"publisher","first-page":"1223960","DOI":"10.3389\/fneur.2023.1223960","volume":"14","author":"KA Edwards","year":"2023","unstructured":"Edwards KA, Lange RT, Lippa SM, Brickell TA, Gill JM, French LM (2023) Serum GFAP, NfL, and tau concentrations are associated with worse neurobehavioral functioning following mild, moderate, and severe TBI: a cross-sectional multiple-cohort study. Front Neurol 14:1223960\u20131223960. https:\/\/doi.org\/10.3389\/fneur.2023.1223960","journal-title":"Front Neurol"},{"issue":"4","key":"1752_CR73","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14283\/jpad.2023.83","volume":"10","author":"A Feizpour","year":"2023","unstructured":"Feizpour A, Dor\u00e9 V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R et al (2023) Two-year prognostic utility of plasma p217\u2009+\u2009tau across the Alzheimer\u2019s continuum. J Prev Alzheimers Dis 10(4):828\u2013836. https:\/\/doi.org\/10.14283\/jpad.2023.83","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"1752_CR171","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.3390\/ijms26062561","volume":"26","author":"C Fern\u00e1ndez-Pereira","year":"2025","unstructured":"Fern\u00e1ndez-Pereira C, Ag\u00eds-Balboa RC (2025) The insulin-like growth factor family as a potential peripheral biomarker in psychiatric disorders: a systematic review. Int J Mol Sci 26(6):2561\u20132561. https:\/\/doi.org\/10.3390\/ijms26062561","journal-title":"Int J Mol Sci"},{"key":"1752_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1476248","author":"C de Fern\u00e1ndez-Pereira","year":"2024","unstructured":"Fern\u00e1ndez-Pereira C, Fern\u00e1ndez-Ceballos M, de los \u00c1, Olivares JM, Prieto-Gonz\u00e1lez JM, Ag\u00eds-Balboa RC (2024) Neurofilament light chain plasma levels in major depressive disorder: a brief research report. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2024.1476248","journal-title":"Front Psychiatry"},{"issue":"4","key":"1752_CR156","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1002\/alz.70086","volume":"21","author":"E Fertan","year":"2025","unstructured":"Fertan E, Lam JYL, Albertini G, Dewilde M, Wu Y, Akingbade OES et al (2025) Lecanemab preferentially binds to smaller aggregates present at early Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 21(4):e70086\u2013e70086. https:\/\/doi.org\/10.1002\/alz.70086","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"2","key":"1752_CR54","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/alz.13485","volume":"20","author":"KE Foley","year":"2024","unstructured":"Foley KE, Winder Z, Sudduth TL, Martin BJ, Nelson PT, Jicha GA et al (2024) Alzheimer\u2019s disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort. Alzheimers Dement 20(2):1374\u20131386. https:\/\/doi.org\/10.1002\/alz.13485","journal-title":"Alzheimers Dement"},{"key":"1752_CR147","volume-title":"FDA grants clearance for Lumipulse G pTau217\/\u03b2-amyloid 1\u201342 plasma ratio test for Alzheimer\u2019s disease assessment","author":"Food and Drug Administration","year":"2025","unstructured":"Food and Drug Administration (2025) FDA grants clearance for Lumipulse G pTau217\/\u03b2-amyloid 1\u201342 plasma ratio test for Alzheimer\u2019s disease assessment. US Food and Drug Administration, Washington"},{"key":"1752_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12375","author":"CJ Fowler","year":"2022","unstructured":"Fowler CJ, Stoops E, Rainey-Smith SR, Vanmechelen E, Vanbrabant J, Dewit N et al (2022) Plasma p\u2010tau181\/A\u03b2 1\u201042 ratio predicts A\u03b2\u2010PET status and correlates with CSF\u2010p\u2010tau181\/A\u03b2 1\u201042 and future cognitive decline. Alzheimers Dement Diagn Assess Dis Monit. https:\/\/doi.org\/10.1002\/dad2.12375","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"8","key":"1752_CR87","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/alz.12508","volume":"18","author":"B Frank","year":"2022","unstructured":"Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA et al (2022) Plasma p-tau 181 shows stronger network association to Alzheimer\u2019s disease dementia than neurofilament light and total tau. Alzheimers Dement 18(8):1523\u20131536. https:\/\/doi.org\/10.1002\/alz.12508","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1752_CR25","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1002\/alz.14179","volume":"20","author":"JN Geigenm\u00fcller","year":"2024","unstructured":"Geigenm\u00fcller JN, Tari AR, Wisloff U, Walker TL (2024) The relationship between adult hippocampal neurogenesis and cognitive impairment in Alzheimer\u2019s disease. Alzheimers Dement 20(10):7369\u20137383. https:\/\/doi.org\/10.1002\/alz.14179","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1752_CR82","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000524390","volume":"51","author":"M Gerards","year":"2022","unstructured":"Gerards M, Schild AK, Meiberth D, Rostamzadeh A, Vehreschild JJ, Wingen-Heimann S et al (2022) Alzheimer\u2019s disease plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Dement Geriatr Cogn Disord 51(2):182\u2013192. https:\/\/doi.org\/10.1159\/000524390","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1752_CR1","doi-asserted-by":"publisher","first-page":"120805","DOI":"10.1016\/j.jns.2023.120805","volume":"453","author":"G Giacomucci","year":"2023","unstructured":"Giacomucci G, Mazzeo S, Crucitti C, Ingannato A, Bagnoli S, Padiglioni S et al (2023) Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment. J Neurol Sci 453:120805\u2013120805. https:\/\/doi.org\/10.1016\/j.jns.2023.120805","journal-title":"J Neurol Sci"},{"issue":"1","key":"1752_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13311-014-0313-y","volume":"12","author":"GK Gouras","year":"2015","unstructured":"Gouras GK, Olsson TT, Hansson O (2015) \u03b2-Amyloid peptides and amyloid plaques in Alzheimer\u2019s disease. Neurother J Am Soc Exp Neurother 12(1):3\u201311. https:\/\/doi.org\/10.1007\/s13311-014-0313-y","journal-title":"Neurother J Am Soc Exp Neurother"},{"issue":"6","key":"1752_CR40","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/s41591-025-03605-x","volume":"31","author":"G Grande","year":"2025","unstructured":"Grande G, Valletta M, Rizzuto D, Xia X, Qiu C, Orsini N et al (2025) Blood-based biomarkers of Alzheimer\u2019s disease and incident dementia in the community. Nat Med 31(6):2027\u20132035. https:\/\/doi.org\/10.1038\/s41591-025-03605-x","journal-title":"Nat Med"},{"key":"1752_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biom15091310","author":"A Grewal","year":"2025","unstructured":"Grewal A, Raikundalia S, Zaia J, Sethi MK (2025) Overview of proteomic analysis of amyloid plaques and neurofibrillary tangles in Alzheimer\u2019s disease. Biomolecules. https:\/\/doi.org\/10.3390\/biom15091310","journal-title":"Biomolecules"},{"issue":"1","key":"1752_CR142","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-023-01174-0","volume":"15","author":"Y Guo","year":"2023","unstructured":"Guo Y, Shen XN, Wang HF, Chen SD, Zhang YR, Chen SF et al (2023) The dynamics of plasma biomarkers across the Alzheimer\u2019s continuum. Alzheimers Res Ther 15(1):31\u201331. https:\/\/doi.org\/10.1186\/s13195-023-01174-0","journal-title":"Alzheimers Res Ther"},{"issue":"13","key":"1752_CR106","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2174\/1567205018666210219105949","volume":"17","author":"JR Hall","year":"2021","unstructured":"Hall JR, Johnson LA, Peterson M, Julovich D, Como T, O\u2019Bryant SE (2021) Relationship of neurofilament light (NfL) and cognitive performance in a sample of Mexican Americans with normal cognition, mild cognitive impairment and dementia. Curr Alzheimer Res 17(13):1214\u20131220. https:\/\/doi.org\/10.2174\/1567205018666210219105949","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"1752_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Vergallo A (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17(9):580\u2013589. https:\/\/doi.org\/10.1038\/s41582-021-00520-w","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1752_CR164","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging 3(5):506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3","journal-title":"Nat Aging"},{"issue":"10","key":"1752_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-v","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12(10):383\u2013388. https:\/\/doi.org\/10.1016\/0165-6147(91)90609-v","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1752_CR162","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5582\/ddt.2025.01055","volume":"19","author":"S Hu","year":"2025","unstructured":"Hu S, Yu H, Gao J (2025) The pTau217\/A\u03b21\u201342 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer\u2019s disease. Drug Discov Ther 19(3):208\u2013209. https:\/\/doi.org\/10.5582\/ddt.2025.01055","journal-title":"Drug Discov Ther"},{"issue":"12","key":"1752_CR83","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/cns.13962","volume":"28","author":"Y Huang","year":"2022","unstructured":"Huang Y, Li Y, Xie F, Guo Q (2022) Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. CNS Neurosci Ther 28(12):2195\u20132205. https:\/\/doi.org\/10.1111\/cns.13962","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"1752_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.nic.2005.09.009","volume":"15","author":"BP Imbimbo","year":"2005","unstructured":"Imbimbo BP, Lombard J, Pomara N (2005) Pathophysiology of Alzheimer\u2019s disease. Neuroimaging Clin N Am 15(4):727\u2013753. https:\/\/doi.org\/10.1016\/j.nic.2005.09.009. ix","journal-title":"Neuroimaging Clin N Am"},{"key":"1752_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1375302","author":"A Ingannato","year":"2024","unstructured":"Ingannato A, Bagnoli S, Mazzeo S, Giacomucci G, Bessi V, Ferrari C et al (2024) Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2024.1375302","journal-title":"Front Endocrinol"},{"key":"1752_CR127","unstructured":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS) Plataforma de Biomarcadores en Fluidos Biol\u00f3gicos (SIMOA HD-X). https:\/\/www.idisantiago.es\/plataformas-de-apoyo-comun\/plataforma-de-biomarcadores-en-fluidos-biologicos-simoa-hd-x\/. Cited 4 Mar 2026"},{"issue":"2","key":"1752_CR166","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","volume":"31","author":"T Islam","year":"2025","unstructured":"Islam T, Hill E, Abrahamson EE, Servaes S, Smirnov DS, Zeng X et al (2025) Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer\u2019s disease. Nat Med 31(2):574\u2013588. https:\/\/doi.org\/10.1038\/s41591-024-03400-0","journal-title":"Nat Med"},{"issue":"4","key":"1752_CR150","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack","year":"2008","unstructured":"Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D et al (2008) The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging JMRI 27(4):685\u2013691. https:\/\/doi.org\/10.1002\/jmri.21049","journal-title":"J Magn Reson Imaging JMRI"},{"issue":"2","key":"1752_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207\u2013216. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0","journal-title":"Lancet Neurol"},{"issue":"4","key":"1752_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"3","key":"1752_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.14283\/jfa.2022.17","volume":"11","author":"ME Jacob","year":"2022","unstructured":"Jacob ME, O\u2019Donnell A, Samra J, Gonzales MM, Satizabal C, Pase MP et al (2022) Grip strength, gait speed and plasma markers of neurodegeneration in asymptomatic middle-aged and older adults. J Frailty Aging 11(3):291\u2013298. https:\/\/doi.org\/10.14283\/jfa.2022.17","journal-title":"J Frailty Aging"},{"issue":"4","key":"1752_CR76","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E et al (2023a) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"issue":"5","key":"1752_CR149","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O (2023b) Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol 80(5):516\u2013516. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199","journal-title":"JAMA Neurol"},{"issue":"1","key":"1752_CR118","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A et al (2016) Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 6(1):26801\u201326801. https:\/\/doi.org\/10.1038\/srep26801","journal-title":"Sci Rep"},{"key":"1752_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.749649","author":"B Jiao","year":"2021","unstructured":"Jiao B, Liu H, Guo L, Liao X, Zhou Y, Weng L et al (2021) Performance of plasma amyloid \u03b2, total tau, and neurofilament light chain in the identification of probable Alzheimer\u2019s disease in South China. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2021.749649","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1752_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19(5):422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"issue":"3","key":"1752_CR92","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/medicina58030433","volume":"58","author":"D Kern","year":"2022","unstructured":"Kern D, Khalil M, Pirpamer L, Buchmann A, Hofer E, Dal-Bianco P et al (2022) Serum NfL in Alzheimer dementia: results of the Prospective Dementia Registry Austria. Med (Mex) 58(3):433\u2013433. https:\/\/doi.org\/10.3390\/medicina58030433","journal-title":"Med (Mex)"},{"issue":"10","key":"1752_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1752_CR123","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3233\/JAD-200900","volume":"79","author":"I Koychev","year":"2021","unstructured":"Koychev I, Jansen K, Dette A, Shi L, Holling H, Blood-Based ATN (2021) Biomarkers of Alzheimer\u2019s disease: a meta-analysis. J Alzheimers Dis 79(1):177\u2013195. https:\/\/doi.org\/10.3233\/JAD-200900","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1752_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/ADR-230156","volume":"8","author":"G Krishna","year":"2024","unstructured":"Krishna G, Thangaraju Sivakumar P, Dahale AB, Subramanian S (2024) Potential utility of plasma biomarker panels in differential diagnosis of Alzheimer\u2019s disease. J Alzheimers Dis Rep 8(1):1\u20137. https:\/\/doi.org\/10.3233\/ADR-230156","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"1752_CR108","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40120-020-00189-1","volume":"9","author":"M Kritikos","year":"2020","unstructured":"Kritikos M, Clouston SAP, Diminich ED, Deri Y, Yang X, Carr M et al (2020) Pathway analysis for plasma \u03b2-amyloid, tau and neurofilament light (ATN) in World Trade Center responders at midlife. Neurol Ther 9(1):159\u2013171. https:\/\/doi.org\/10.1007\/s40120-020-00189-1","journal-title":"Neurol Ther"},{"key":"1752_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12502","author":"HS Kwon","year":"2023","unstructured":"Kwon HS, Lee E, Kim H, Park S, Park H, Jeong JH et al (2023) Predicting amyloid PET positivity using plasma p-tau181 and other blood\u2010based biomarkers. Alzheimers Dement Diagn Assess Dis Monit. https:\/\/doi.org\/10.1002\/dad2.12502","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"Supplement1","key":"1752_CR124","doi-asserted-by":"publisher","first-page":"17416","DOI":"10.4049\/jimmunol.200.Supp.174.16","volume":"200","author":"J Lambert","year":"2018","unstructured":"Lambert J, Vonk A, Mendes M, Song L, Svancara D, Baig S et al (2018) Comparison of two platforms for the measurement of fg\/mL concentrations of protein biomarkers using single molecule arrays and digital ELISA: the benchtop reader Quanterix SR-X\u2122, and the fully automated analyzer HD-1\u2122. J Immunol 200(Supplement1):17416\u201317416. https:\/\/doi.org\/10.4049\/jimmunol.200.Supp.174.16","journal-title":"J Immunol"},{"issue":"1","key":"1752_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P et al (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther 10(1):71\u201371. https:\/\/doi.org\/10.1186\/s13195-018-0404-9","journal-title":"Alzheimers Res Ther"},{"issue":"S2","key":"1752_CR121","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","volume":"8","author":"D Li","year":"2019","unstructured":"Li D, Mielke MM (2019) An Update on Blood-Based Markers of Alzheimer\u2019s Disease Using the SiMoA Platform. Neurol Ther 8(S2):73\u201382. https:\/\/doi.org\/10.1007\/s40120-019-00164-5","journal-title":"Neurol Ther"},{"issue":"1","key":"1752_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13195-024-01458-z","volume":"16","author":"Z Liu","year":"2024","unstructured":"Liu Z, Shi D, Cai Y, Li A, Lan G, Sun P et al (2024) Pathophysiology characterization of Alzheimer\u2019s disease in South China\u2019s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS). Alzheimers Res Ther 16(1):84\u201384. https:\/\/doi.org\/10.1186\/s13195-024-01458-z","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"1752_CR141","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1007\/s12035-025-04767-y","volume":"62","author":"M Lomi","year":"2025","unstructured":"Lomi M, Geraci F, Del Seppia C, Dolciotti C, Del Carratore R, Bongioanni P (2025) Biomarker profile in peripheral blood cells related to Alzheimer\u2019s disease. Mol Neurobiol 62(7):8949\u20138964. https:\/\/doi.org\/10.1007\/s12035-025-04767-y","journal-title":"Mol Neurobiol"},{"key":"1752_CR13","doi-asserted-by":"publisher","first-page":"1693840","DOI":"10.3389\/fnagi.2025.1693840","volume":"17","author":"L Lv","year":"2025","unstructured":"Lv L, Guo H, Zhao Z, Zhao X (2025) Structural and microstructural changes in white and gray matter across the Alzheimer\u2019s disease continuum. Front Aging Neurosci 17:1693840\u20131693840. https:\/\/doi.org\/10.3389\/fnagi.2025.1693840","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1752_CR99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-021-00944-y","volume":"13","author":"JD Marks","year":"2021","unstructured":"Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR et al (2021) Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther 13(1):199\u2013199. https:\/\/doi.org\/10.1186\/s13195-021-00944-y","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1752_CR148","doi-asserted-by":"publisher","first-page":"e16089","DOI":"10.1111\/ene.16089","volume":"31","author":"S Mazzeo","year":"2024","unstructured":"Mazzeo S, Ingannato A, Giacomucci G, Manganelli A, Moschini V, Balestrini J et al (2024) Plasma neurofilament light chain predicts Alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study. Eur J Neurol 31(1):e16089\u2013e16089. https:\/\/doi.org\/10.1111\/ene.16089","journal-title":"Eur J Neurol"},{"issue":"3","key":"1752_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 7(3):263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"8","key":"1752_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Fowler NR (2024) Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol 20(8):495\u2013504. https:\/\/doi.org\/10.1038\/s41582-024-00989-1","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1752_CR100","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K et al (2021) Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol 78(9):1108\u20131108. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293","journal-title":"JAMA Neurol"},{"issue":"1","key":"1752_CR144","doi-asserted-by":"publisher","first-page":"22633","DOI":"10.1038\/s41598-024-72265-7","volume":"14","author":"OM Morris","year":"2024","unstructured":"Morris OM, Toprakcioglu Z, R\u00f6ntgen A, Cali M, Knowles TPJ, Vendruscolo M (2024) Aggregation of the amyloid-\u03b2 peptide (A\u03b240) within condensates generated through liquid-liquid phase separation. Sci Rep 14(1):22633\u201322633. https:\/\/doi.org\/10.1038\/s41598-024-72265-7","journal-title":"Sci Rep"},{"issue":"1","key":"1752_CR66","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1021\/acschemneuro.2c00636","volume":"14","author":"M Ni","year":"2023","unstructured":"Ni M, Zhu ZH, Gao F, Dai LB, Lv XY, Wang Q et al (2023) Plasma core Alzheimer\u2019s disease biomarkers predict amyloid deposition burden by positron emission tomography in chinese individuals with cognitive decline. ACS Chem Neurosci 14(1):170\u2013179. https:\/\/doi.org\/10.1021\/acschemneuro.2c00636","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"1752_CR11","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M et al (2023) Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Dement 19(11):5095\u20135102. https:\/\/doi.org\/10.1002\/alz.13103","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1752_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15(7):673\u2013684. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"key":"1752_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178564","author":"V Pacoova Dal Maschio","year":"2025","unstructured":"Pacoova Dal Maschio V, Roveta F, Bonino L, Boschi S, Rainero I, Rubino E (2025) The role of blood-based biomarkers in transforming Alzheimer\u2019s disease research and clinical management: a review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26178564","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1752_CR154","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D et al (2025) Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol 82(7):655\u2013655. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232","journal-title":"JAMA Neurol"},{"issue":"8","key":"1752_CR47","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al (2020) Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"1752_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.832700","author":"FF Pan","year":"2022","unstructured":"Pan FF, Huang Q, Wang Y, Wang YF, Guan YH, Xie F et al (2022) Non-linear character of plasma amyloid beta over the course of cognitive decline in Alzheimer\u2019s continuum. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.832700","journal-title":"Front Aging Neurosci"},{"key":"1752_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.887498","author":"T Parvizi","year":"2022","unstructured":"Parvizi T, K\u00f6nig T, Wurm R, Silvaieh S, Altmann P, Klotz S et al (2022) Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.887498","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1752_CR146","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12551-023-01052-x","volume":"15","author":"IY Petrushanko","year":"2023","unstructured":"Petrushanko IY, Mitkevich VA, Makarov AA (2023) Effect of \u03b2-amyloid on blood-brain barrier properties and function. Biophys Rev 15(2):183\u2013197. https:\/\/doi.org\/10.1007\/s12551-023-01052-x","journal-title":"Biophys Rev"},{"issue":"3","key":"1752_CR14","doi-asserted-by":"publisher","first-page":"fcac109","DOI":"10.1093\/braincomms\/fcac109","volume":"4","author":"V Planche","year":"2022","unstructured":"Planche V, Manjon JV, Mansencal B, Lanuza E, Tourdias T, Catheline G et al (2022) Structural progression of Alzheimer\u2019s disease over decades: the MRI staging scheme. Brain Commun 4(3):fcac109\u2013fcac109. https:\/\/doi.org\/10.1093\/braincomms\/fcac109","journal-title":"Brain Commun"},{"key":"1752_CR17","doi-asserted-by":"publisher","first-page":"109581","DOI":"10.1016\/j.jneumeth.2022.109581","volume":"374","author":"C Platero","year":"2022","unstructured":"Platero C (2022) Categorical predictive and disease progression modeling in the early stage of Alzheimer\u2019s disease. J Neurosci Methods 374:109581\u2013109581. https:\/\/doi.org\/10.1016\/j.jneumeth.2022.109581","journal-title":"J Neurosci Methods"},{"issue":"2","key":"1752_CR143","doi-asserted-by":"publisher","first-page":"658","DOI":"10.14336\/AD.2024.0286","volume":"16","author":"JA Pradeepkiran","year":"2024","unstructured":"Pradeepkiran JA, Baig J, Islam MA, Kshirsagar S, Reddy PH (2024) Amyloid-\u03b2 and phosphorylated tau are the key biomarkers and predictors of Alzheimer\u2019s disease. Aging Dis 16(2):658\u2013682. https:\/\/doi.org\/10.14336\/AD.2024.0286","journal-title":"Aging Dis"},{"issue":"2","key":"1752_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 25(2):277\u2013283. https:\/\/doi.org\/10.1038\/s41591-018-0304-3","journal-title":"Nat Med"},{"issue":"1","key":"1752_CR145","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-024-01529-1","volume":"16","author":"L Preis","year":"2024","unstructured":"Preis L, Villringer K, Brosseron F, D\u00fczel E, Jessen F, Petzold GC et al (2024) Assessing blood-brain barrier dysfunction and its association with Alzheimer\u2019s pathology, cognitive impairment and neuroinflammation. Alzheimers Res Ther 16(1):172\u2013172. https:\/\/doi.org\/10.1186\/s13195-024-01529-1","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1752_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and preclinical Alzheimer\u2019s disease. Ann Neurol 45(3):358\u2013368. https:\/\/doi.org\/10.1002\/1531-8249)45:3%3C358::aid-ana12%3E3.0.co;2-x","journal-title":"Ann Neurol"},{"key":"1752_CR163","unstructured":"Quanterix (2024) Quanterix granted Breakthrough Device designation from U.S. FDA for blood-based p-Tau 217 test for Alzheimer\u2019s disease. https:\/\/www.quanterix.com\/press-releases\/quanterix-granted-breakthrough-device-designation-from-u-s-fda-for-blood-based-p-tau-217-test-for-alzheimers-disease\/.\u00a0Accessed 26 Mar 2024"},{"key":"1752_CR126","unstructured":"Quanterix Simoa HD\u2013X Analyzer\u00ae \u2013 Automated Immunoassays. Simoa HD\u2013X Analyzer\u00ae \u2013 Automated Immunoassays. https:\/\/www.quanterix.com\/simoa-hd-x-analyzer\/"},{"issue":"1","key":"1752_CR32","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O et al (2025) Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement J Alzheimers Assoc 21(1):e14338\u2013e14338. https:\/\/doi.org\/10.1002\/alz.14338","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"2","key":"1752_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13205-022-03123-4","volume":"12","author":"YL Rao","year":"2022","unstructured":"Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A (2022) Hippocampus and its involvement in Alzheimer\u2019s disease: a review. 3 Biotech 12(2):55\u201355. https:\/\/doi.org\/10.1007\/s13205-022-03123-4","journal-title":"3 Biotech"},{"issue":"3","key":"1752_CR77","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-210391","volume":"87","author":"B Rippon","year":"2022","unstructured":"Rippon B, Palta P, Tahmi M, Sherwood G, Soto L, Cespedes S et al (2022) Plasma amyloid and in vivo brain amyloid in late middle-aged hispanics. J Alzheimers Dis 87(3):1229\u20131238. https:\/\/doi.org\/10.3233\/JAD-210391","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1752_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595\u2013599. https:\/\/doi.org\/10.1038\/nbt.1641","journal-title":"Nat Biotechnol"},{"key":"1752_CR18","doi-asserted-by":"publisher","first-page":"103615","DOI":"10.1016\/j.nicl.2024.103615","volume":"42","author":"M Riverol","year":"2024","unstructured":"Riverol M, R\u00edos-Rivera MM, Imaz-Aguayo L, Solis-Barquero SM, Arrondo C, Montoya-Murillo G et al (2024) Structural neuroimaging changes associated with subjective cognitive decline from a clinical sample. NeuroImage Clin 42:103615\u2013103615. https:\/\/doi.org\/10.1016\/j.nicl.2024.103615","journal-title":"NeuroImage Clin"},{"issue":"1424","key":"1752_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1098\/rstb.2002.1102","volume":"357","author":"MD Rugg","year":"2002","unstructured":"Rugg MD, Otten LJ, Henson RNA (2002) The neural basis of episodic memory: evidence from functional neuroimaging. Philos Trans R Soc Lond B Biol Sci 357(1424):1097\u20131110. https:\/\/doi.org\/10.1098\/rstb.2002.1102","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"2","key":"1752_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1567205013666160629081956","volume":"14","author":"CA Sanchez-Catasus","year":"2017","unstructured":"Sanchez-Catasus CA, Stormezand GN, van Laar PJ, De Deyn PP, Sanchez MA, Dierckx RAJO (2017) FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT). Curr Alzheimer Res 14(2):127\u2013142. https:\/\/doi.org\/10.2174\/1567205013666160629081956","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"1752_CR102","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1111\/ene.14999","volume":"28","author":"R Santangelo","year":"2021","unstructured":"Santangelo R, Agosta F, Masi F, Spinelli EG, Cecchetti G, Caso F et al (2021) Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer\u2019s disease. Eur J Neurol 28(9):2980\u20132988. https:\/\/doi.org\/10.1111\/ene.14999","journal-title":"Eur J Neurol"},{"issue":"17","key":"1752_CR43","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA et al (2019) High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93(17):e1647\u2013e1659. https:\/\/doi.org\/10.1212\/WNL.0000000000008081","journal-title":"Neurology"},{"issue":"10","key":"1752_CR173","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","volume":"5","author":"M Sch\u00f6ll","year":"2024","unstructured":"Sch\u00f6ll M, Verberk IMW, Del Campo M, Delaby C, Therriault J, Chong JR et al (2024) Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease. Lancet Healthy Longev 5(10):100630\u2013100630. https:\/\/doi.org\/10.1016\/j.lanhl.2024.07.013","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"1752_CR132","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1373\/clinchem.2004.039735","volume":"51","author":"NSM Schoonenboom","year":"2005","unstructured":"Schoonenboom NSM, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ et al (2005) Effects of processing and storage conditions on amyloid beta (1\u201342) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51(1):189\u2013195. https:\/\/doi.org\/10.1373\/clinchem.2004.039735","journal-title":"Clin Chem"},{"issue":"3","key":"1752_CR78","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3233\/JAD-215096","volume":"85","author":"CR Schubert","year":"2022","unstructured":"Schubert CR, Paulsen AJ, Pinto AA, Merten N, Cruickshanks KJ (2022) Effect of long-term storage on the reliability of blood biomarkers for Alzheimer\u2019s disease and neurodegeneration. J Alzheimers Dis 85(3):1021\u20131029. https:\/\/doi.org\/10.3233\/JAD-215096","journal-title":"J Alzheimers Dis"},{"issue":"Pt 4","key":"1752_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/brain\/awp007","volume":"132","author":"N Schuff","year":"2009","unstructured":"Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ et al (2009) MRI of hippocampal volume loss in early Alzheimer\u2019s disease in relation to ApoE genotype and biomarkers. Brain J Neurol 132(Pt 4):1067\u20131077. https:\/\/doi.org\/10.1093\/brain\/awp007","journal-title":"Brain J Neurol"},{"issue":"1","key":"1752_CR157","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G et al (2023) Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurother J Am Soc Exp Neurother 20(1):195\u2013206. https:\/\/doi.org\/10.1007\/s13311-022-01308-6","journal-title":"Neurother J Am Soc Exp Neurother"},{"issue":"2","key":"1752_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol Rev 81(2):741\u2013766. https:\/\/doi.org\/10.1152\/physrev.2001.81.2.741","journal-title":"Physiol Rev"},{"issue":"6","key":"1752_CR58","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s11357-024-01130-2","volume":"46","author":"KR Sewell","year":"2024","unstructured":"Sewell KR, Rainey-Smith SR, Pedrini S, Peiffer JJ, Sohrabi HR, Taddei K et al (2024) The impact of exercise on blood-based biomarkers of Alzheimer\u2019s disease in cognitively unimpaired older adults. GeroScience 46(6):5911\u20135923. https:\/\/doi.org\/10.1007\/s11357-024-01130-2","journal-title":"GeroScience"},{"issue":"1","key":"1752_CR139","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40364-025-00829-4","volume":"13","author":"N Sharma","year":"2025","unstructured":"Sharma N, Kim D, Sharma H, Kim MI, Lee H, Kim M et al (2025) Bridging the barrier: insights into blood biomarkers and therapeutic strategies targeting choroid plexus and BBB dysfunction in alzheimer\u2019s disease. Biomark Res 13(1):116\u2013116. https:\/\/doi.org\/10.1186\/s40364-025-00829-4","journal-title":"Biomark Res"},{"issue":"6","key":"1752_CR65","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/ene.15762","volume":"30","author":"A Silva-Sp\u00ednola","year":"2023","unstructured":"Silva-Sp\u00ednola A, Lima M, Leit\u00e3o MJ, Bernardes C, Dur\u00e3es J, Duro D et al (2023) Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia. Eur J Neurol 30(6):1565\u20131573. https:\/\/doi.org\/10.1111\/ene.15762","journal-title":"Eur J Neurol"},{"issue":"7","key":"1752_CR104","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J et al (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 17(7):1145\u20131156. https:\/\/doi.org\/10.1002\/alz.12283","journal-title":"Alzheimers Dement"},{"key":"1752_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/alz.067980","author":"J Stevenson","year":"2022","unstructured":"Stevenson J, Rahmouni N, Chamoun M, Benedet AL, Stevenson A, Pallen V et al (2022) TRIAD multi-dimensional biobank for biomarker discovery. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.067980","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1752_CR107","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13195-020-00738-8","volume":"12","author":"J Stockmann","year":"2020","unstructured":"Stockmann J, Verberk IMW, Timmesfeld N, Denz R, Budde B, Lange-Leifhelm J et al (2020) Amyloid-\u03b2 misfolding as a plasma biomarker indicates risk for future clinical Alzheimer\u2019s disease in individuals with subjective cognitive decline. Alzheimers Res Ther 12(1):169\u2013169. https:\/\/doi.org\/10.1186\/s13195-020-00738-8","journal-title":"Alzheimers Res Ther"},{"key":"1752_CR110","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","volume":"94","author":"MA Sugarman","year":"2020","unstructured":"Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD et al (2020) A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease. Neurobiol Aging 94:60\u201370. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.05.011","journal-title":"Neurobiol Aging"},{"key":"1752_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.963845","author":"Q Sun","year":"2022","unstructured":"Sun Q, Ni J, Wei M, Long S, Li T, Fan D et al (2022) Plasma \u03b2-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer\u2019s disease dementia in Chinese individuals. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.963845","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1752_CR134","doi-asserted-by":"publisher","first-page":"e12439","DOI":"10.1002\/dad2.12439","volume":"15","author":"AL Sunde","year":"2023","unstructured":"Sunde AL, Alsnes IV, Aarsland D, Ashton NJ, Tovar-Rios DA, De Santis G et al (2023) Preanalytical stability of plasma biomarkers for Alzheimer\u2019s disease pathology. Alzheimers Dement Amst Neth 15(2):e12439\u2013e12439. https:\/\/doi.org\/10.1002\/dad2.12439","journal-title":"Alzheimers Dement Amst Neth"},{"issue":"7","key":"1752_CR135","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.nrl.2024.08.002","volume":"40","author":"M Su\u00e1rez-Calvet","year":"2025","unstructured":"Su\u00e1rez-Calvet M, Abdelnour C, Alcolea D, Mendi\u00f3roz-Iriarte M, Balasa M, Morenas-Rodr\u00edguez E et al (2025) Biomarcadores en sangre para la enfermedad de Alzheimer: posicionamiento y recomendaciones de uso del Grupo de Estudio de Conducta y Demencias de la Sociedad Espa\u00f1ola de Neurolog\u00eda. Neurolog\u00eda 40(7):700\u2013712. https:\/\/doi.org\/10.1016\/j.nrl.2024.08.002","journal-title":"Neurolog\u00eda"},{"issue":"7","key":"1752_CR128","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.nrleng.2025.07.004","volume":"40","author":"M Su\u00e1rez-Calvet","year":"2025","unstructured":"Su\u00e1rez-Calvet M, Abdelnour C, Alcolea D, Mendi\u00f3roz-Iriarte M, Balasa M, Morenas-Rodr\u00edguez E et al (2025) Blood-based biomarkers for Alzheimer\u2019s disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia 40(7):700\u2013712. https:\/\/doi.org\/10.1016\/j.nrleng.2025.07.004","journal-title":"Neurologia"},{"issue":"5","key":"1752_CR105","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/ene.14704","volume":"28","author":"T Tanaka","year":"2021","unstructured":"Tanaka T, Ruifen JC, Nai Y, Tan CH, Lim CZJ, Zhang Y et al (2021) Head-to\u2010head comparison of amplified plasmonic exosome A\u03b242 platform and single\u2010molecule array immunoassay in a memory clinic cohort. Eur J Neurol 28(5):1479\u20131489. https:\/\/doi.org\/10.1111\/ene.14704","journal-title":"Eur J Neurol"},{"issue":"6","key":"1752_CR72","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/alz.13022","volume":"19","author":"P Thanapornsangsuth","year":"2023","unstructured":"Thanapornsangsuth P, Booncharoen K, Luechaipanit W, Supharatpariyakorn T, Sarutikriangkri Y, Tangnimitchok S et al (2023) Prospective evaluation of plasma phosphorylated tau in a real-life memory clinic in Thailand. Alzheimers Dement 19(6):2745\u20132749. https:\/\/doi.org\/10.1002\/alz.13022","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1752_CR70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL et al (2023) Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol 80(2):188\u2013188. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","journal-title":"JAMA Neurol"},{"issue":"1","key":"1752_CR74","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1038\/s41598-023-29704-8","volume":"13","author":"M Truffi","year":"2023","unstructured":"Truffi M, Garofalo M, Ricciardi A, Cotta Ramusino M, Perini G, Scaranzin S et al (2023) Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study. Sci Rep 13(1):4041\u20134041. https:\/\/doi.org\/10.1038\/s41598-023-29704-8","journal-title":"Sci Rep"},{"issue":"5","key":"1752_CR4","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1007\/s12035-023-03736-7","volume":"61","author":"W Tsering","year":"2024","unstructured":"Tsering W, Prokop S (2024) Neuritic Plaques - Gateways to Understanding Alzheimer\u2019s Disease. Mol Neurobiol 61(5):2808\u20132821. https:\/\/doi.org\/10.1007\/s12035-023-03736-7","journal-title":"Mol Neurobiol"},{"issue":"10","key":"1752_CR89","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41380-022-01675-8","volume":"27","author":"AA Tsiknia","year":"2022","unstructured":"Tsiknia AA, Edland SD, Sundermann EE, Reas ET, Brewer JB, Galasko D et al (2022) Sex differences in plasma p-tau181 associations with Alzheimer\u2019s disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry 27(10):4314\u20134322. https:\/\/doi.org\/10.1038\/s41380-022-01675-8","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1752_CR93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14283\/jpad.2021.70","volume":"9","author":"C Udeh-Momoh","year":"2022","unstructured":"Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, J\u00f6nsson L et al (2022) Blood derived amyloid biomarkers for Alzheimer\u2019s disease prevention. J Prev Alzheimers Dis 9(1):12\u201321. https:\/\/doi.org\/10.14283\/jpad.2021.70","journal-title":"J Prev Alzheimers Dis"},{"key":"1752_CR160","unstructured":"U.S. Food and Drug Administration. FDA (2024) KISUNLA\u2122 (donanemab-azbt) injection, prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf"},{"issue":"1","key":"1752_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11357-023-00876-5","volume":"46","author":"J van Arendonk","year":"2023","unstructured":"van Arendonk J, Wolters FJ, Neitzel J, Vinke EJ, Vernooij MW, Ghanbari M et al (2023) Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study. GeroScience 46(1):57\u201370. https:\/\/doi.org\/10.1007\/s11357-023-00876-5","journal-title":"GeroScience"},{"issue":"5","key":"1752_CR116","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM et al (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 84(5):648\u2013658. https:\/\/doi.org\/10.1002\/ana.25334","journal-title":"Ann Neurol"},{"issue":"1","key":"1752_CR109","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A et al (2020) Combination of plasma amyloid beta(1\u201342\/1\u201340) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther 12(1):118\u2013118. https:\/\/doi.org\/10.1186\/s13195-020-00682-7","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1752_CR113","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","volume":"15","author":"A Vergallo","year":"2019","unstructured":"Vergallo A, M\u00e9gret L, Lista S, Cavedo E, Zetterberg H, Blennow K et al (2019) Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease. Alzheimers Dement 15(6):764\u2013775. https:\/\/doi.org\/10.1016\/j.jalz.2019.03.009","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1752_CR158","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, Planche V, Lilamand M, Cordonnier C, Soto-Martin M, Mollion H et al (2025) Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis 12(4):100094\u2013100094. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"1752_CR133","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3233\/JAD-200777","volume":"78","author":"M Walter","year":"2020","unstructured":"Walter M, Wiltfang J, Vogelgsang J (2020) Pre-analytical sampling and storage conditions of amyloid-\u03b2 peptides in venous and capillary blood. J Alzheimers Dis JAD 78(2):529\u2013535. https:\/\/doi.org\/10.3233\/JAD-200777","journal-title":"J Alzheimers Dis JAD"},{"issue":"2","key":"1752_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.59706\/aebmedicine.v1i2.7879","volume":"1","author":"MA Walwyn-Hern\u00e1ndez","year":"2023","unstructured":"Walwyn-Hern\u00e1ndez MA, Cepeda-Morales LI, Mateos-Platas O, Cant\u00fa-Flores E (2023) Biomarcadores de la enfermedad de Alzheimer encontrados en pacientes con diabetes mellitus tipo 2: correlaci\u00f3n entre ambas patolog\u00edas. Arch Evid-Based Med 1(2):1\u20137. https:\/\/doi.org\/10.59706\/aebmedicine.v1i2.7879","journal-title":"Arch Evid-Based Med"},{"issue":"1","key":"1752_CR16","doi-asserted-by":"publisher","first-page":"fcae476","DOI":"10.1093\/braincomms\/fcae476","volume":"7","author":"J Wang","year":"2025","unstructured":"Wang J, Liu S, Liang P, Cui B, Wang Z (2025a) Aberrant functional connectivity between the retrosplenial cortex and hippocampal subregions in amnestic mild cognitive impairment and Alzheimer\u2019s disease. Brain Commun 7(1):fcae476\u2013fcae476. https:\/\/doi.org\/10.1093\/braincomms\/fcae476","journal-title":"Brain Commun"},{"key":"1752_CR161","doi-asserted-by":"publisher","first-page":"1554805","DOI":"10.3389\/fnagi.2025.1554805","volume":"17","author":"S Wang","year":"2025","unstructured":"Wang S, Liu D, Li H, Jia X, Zhou H, Yu W et al (2025b) Assessing diagnostic performance of plasma biomarkers in Alzheimer\u2019s disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts. Front Aging Neurosci 17:1554805\u20131554805. https:\/\/doi.org\/10.3389\/fnagi.2025.1554805","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1752_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17(1):5\u201321. https:\/\/doi.org\/10.1038\/nrn.2015.1","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1752_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3174\/ajnr.A0781","volume":"29","author":"FJ Wippold","year":"2008","unstructured":"Wippold FJ, Cairns N, Vo K, Holtzman DM, Morris JC (2008) Neuropathology for the neuroradiologist: plaques and tangles. AJNR Am J Neuroradiol 29(1):18\u201322. https:\/\/doi.org\/10.3174\/ajnr.A0781","journal-title":"AJNR Am J Neuroradiol"},{"key":"1752_CR165","doi-asserted-by":"publisher","DOI":"10.1172\/JCI198725","author":"JK Wisch","year":"2025","unstructured":"Wisch JK, Ances BM (2025) Ruling in, ruling out: the clinical utility of plasma biomarkers in diagnosis of Alzheimer\u2019s disease. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI198725","journal-title":"J Clin Invest"},{"issue":"1","key":"1752_CR131","doi-asserted-by":"publisher","first-page":"e12405","DOI":"10.1002\/dad2.12405","volume":"15","author":"JK Wisch","year":"2023","unstructured":"Wisch JK, Gordon BA, Boerwinkle AH, Luckett PH, Bollinger JG, Ovod V et al (2023) Predicting continuous amyloid PET values with CSF and plasma A\u03b242\/A\u03b240. Alzheimers Dement Diagn Assess Dis Monit 15(1):e12405. https:\/\/doi.org\/10.1002\/dad2.12405","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"1752_CR69","doi-asserted-by":"publisher","first-page":"106356","DOI":"10.1016\/j.nbd.2023.106356","volume":"189","author":"AL Wojda\u0142a","year":"2023","unstructured":"Wojda\u0142a AL, Bellomo G, Gaetani L, Toja A, Chipi E, Shan D et al (2023) Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiol Dis 189:106356\u2013106356. https:\/\/doi.org\/10.1016\/j.nbd.2023.106356","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1752_CR51","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13195-024-01630-5","volume":"16","author":"AL Wojda\u0142a","year":"2024","unstructured":"Wojda\u0142a AL, Vanbrabant J, Bayoumy S, Antwi-Berko D, Bastard NL, van der Flier WM et al (2024) Analytical and clinical performance of eight Simoa\u00ae and Lumipulse\u00ae assays for automated measurement of plasma p-tau181 and p-tau217. Alzheimers Res Ther 16(1):266\u2013266. https:\/\/doi.org\/10.1186\/s13195-024-01630-5","journal-title":"Alzheimers Res Ther"},{"key":"1752_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1288930","author":"L Wu","year":"2024","unstructured":"Wu L, Arvai S, Wang SHJ, Liu AJ, Xu B (2024) Differential diagnosis of mild cognitive impairment of Alzheimer\u2019s disease by Simoa p-tau181 measurements with matching plasma and CSF. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2023.1288930","journal-title":"Front Mol Neurosci"},{"key":"1752_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/0021-9681(61)90141-2","volume":"14","author":"CM Wylie","year":"1961","unstructured":"Wylie CM (1961) Delay in seeking rehabilitation after cerebrovascular accidents. J Chronic Dis 14:442\u2013451. https:\/\/doi.org\/10.1016\/0021-9681(61)90141-2","journal-title":"J Chronic Dis"},{"issue":"1","key":"1752_CR97","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","volume":"13","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Wu X, Wu W, Yi J, Liang X, Ding S et al (2021) Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer\u2019s disease. Alzheimers Res Ther 13(1):123\u2013123. https:\/\/doi.org\/10.1186\/s13195-021-00864-x","journal-title":"Alzheimers Res Ther"},{"key":"1752_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14357","author":"X Xiong","year":"2024","unstructured":"Xiong X, He H, Ye Q, Qian S, Zhou S, Feng F et al (2024) Alzheimer\u2019s disease diagnostic accuracy by fluid and neuroimaging ATN framework. CNS Neurosci Ther. https:\/\/doi.org\/10.1111\/cns.14357","journal-title":"CNS Neurosci Ther"},{"key":"1752_CR15","doi-asserted-by":"publisher","first-page":"1297028","DOI":"10.3389\/fneur.2023.1297028","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Liang L, Wei Y, Liu Y, Li X, Huang J et al (2023) Altered cortical and subcortical morphometric features and asymmetries in the subjective cognitive decline and mild cognitive impairment. Front Neurol 14:1297028\u20131297028. https:\/\/doi.org\/10.3389\/fneur.2023.1297028","journal-title":"Front Neurol"},{"issue":"1","key":"1752_CR79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s40814-022-01200-2","volume":"8","author":"F Yu","year":"2022","unstructured":"Yu F, Han SY, Salisbury D, Pruzin JJ, Geda Y, Caselli RJ et al (2022) Feasibility and preliminary effects of exercise interventions on plasma biomarkers of Alzheimer\u2019s disease in the FIT-AD trial: a randomized pilot study in older adults with Alzheimer\u2019s dementia. Pilot Feasibility Stud 8(1):243\u2013243. https:\/\/doi.org\/10.1186\/s40814-022-01200-2","journal-title":"Pilot Feasibility Stud"},{"key":"1752_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/DNND.S471174","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Bi K, Zhou L, Wang J, Huang L, Sun Y et al (2024) Advances in blood biomarkers for Alzheimer\u2019s disease: ultra-sensitive detection technologies and impact on clinical diagnosis. Degener Neurol Neuromuscul Dis 14:85\u2013102. https:\/\/doi.org\/10.2147\/DNND.S471174","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"1752_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1750-1326-6-27","volume":"6","author":"H Zheng","year":"2011","unstructured":"Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6(1):27\u201327. https:\/\/doi.org\/10.1186\/1750-1326-6-27","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1752_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X (2025) Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16(2):83\u2013120. https:\/\/doi.org\/10.1093\/procel\/pwae026","journal-title":"Protein Cell"},{"key":"1752_CR117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y et al (2017) Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett 650:60\u201364. https:\/\/doi.org\/10.1016\/j.neulet.2017.04.027","journal-title":"Neurosci Lett"},{"issue":"5","key":"1752_CR159","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M et al (2025) Amyloid-related imaging abnormalities with donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol 82(5):461. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065","journal-title":"JAMA Neurol"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-026-01752-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-026-01752-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-026-01752-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:18:50Z","timestamp":1783059530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-026-01752-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1752"],"URL":"https:\/\/doi.org\/10.1007\/s10571-026-01752-4","relation":{},"ISSN":["1573-6830"],"issn-type":[{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}],"article-number":"109"}}